|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's Range||58.85 - 60.55|
|52 Week Range||42.08 - 89.05|
|Beta (3Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.63|
Jim Cramer chats with Jason Gorevic, CEO of Teladoc, about how the telemedicine company is using technology to help expand access to care access globally.
Bank of America Merrill Lynch analyst Allen Lutz highlighted the company’s online therapy brand, BetterHelp, as a potential “crown jewel.”
Teladoc Health Inc NYSE:TDOCView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for TDOC with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TDOC. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold TDOC had net inflows of $1.09 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Teladoc Health, Inc. (NYSE:TDOC), which is in the healthcare services business, and is based in United States, saw a...
Once loved, healthcare stocks are quickly becoming some of the most hated stocks on the planet. It's easy to understand why. Rising drug and procedure costs have made many healthcare stocks targets for various political pundits and presidential candidates. The growing calls for Medicare-For-All and/or socialized medicine has the potential to hit many healthcare firms right in the pocket. When coupled with the general market sell-off, the fast-moving healthcare sector has been a real downer.But that has only made the sector prime for bargain shopping.Even with calls for increased regulation, the healthcare sector still has great long-term potential. Thanks to rising global demand, aging populations as well as new high-tech and high-margined therapies, there are lots of levers for the sector to pull in order to keep the profits coming. And while some healthcare stocks will be hit hard in the regulation wave (like insurance and pharmacy benefit managers), many will be just fine. This could make the recent declines a tantalizing buy-in point for portfolios.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets With the long-term in mind, here are five healthcare stocks that are worth picking up from the wreckage. Abiomed (ABMD)Source: Shutterstock There's a good chance that you've never heard of Abiomed (NASDAQ:ABMD). The firm was only added to the S&P 500 about a year ago. But in that time, it has grown immensely in terms of fundamentals and share price.ABMD produces the Impella, which is the world's smallest heart pump. The device is minimally invasive. That's a key selling point for doctors. Open-heart surgery is risky to begin with, but especially so for patients who have suffered some sort of major cardiovascular event. Impella eliminates many of the risks. Meanwhile, the device can be configured in a variety of applications. Because of this, the Impella is quickly becoming the standard of care for doctors in cardiac surgery.As a result, sales of the device continue to surge. For full-year 2018 results, ABMD managed to see a 30% jump in sales and nearly 43% increase in profits based on continued demand for the game-changing device. And yet, the runway is still long for the firm. There's plenty of market share in the U.S. to gain from older heart pump devices and global demand is still in its infancy. Meanwhile, the firm continues to attract plenty of buyout/M&A buzz and would be a wonderful tuck-in deal for many larger device stocks.However, shares of ABMD are about 35% below their all-time highs from last year. And it isn't cheap from a price-to-earnings perspective either. ABMD is a classic growth stock, but the recent dip makes for an interesting buy-in for those willing to hold it over the long term. Teledoc (TDOC)Source: MayApps207 via WikiMedia Saving money and reducing costs is exactly what any pending regulation in the sector will be all about. That's great news for Teledoc (NASDAQ:TDOC). The firm is the largest player in the growing telemedicine field. Here, patients can fire-up their tablets, PCs or smartphones and speak to a physician in real time, get a diagnosis and even send a prescription to their local pharmacy.Health insurers, benefit managers, employers and consumers seem keen on the idea. More employers are adding the service to their benefits package, with more than 40% of the Fortune 500 offering it in their benefits.This has allowed TDOC to experience some very fast growth over the last few years. between 2016 and what its estimated to pull in this year, Teledoc has seen a staggering 64% compound annual growth rate in terms of revenues. Meanwhile, the firm is finally starting to turn those revenues into meaningful and growing profits.And the growth could continue. TDOC has moved into the mental health arena and has been smartly buying smaller rivals to add instant market share. Meanwhile, more companies continue to see the benefits of adding the platform to their Human Resources package. * The 10 Best Stocks for 2019 -- So Far All in all, TDOC is a high growth healthcare stock that is now trading much lower than expected. Amgen (AMGN)Source: Shutterstock As one of biotech and healthcare's elder statesmen, Amgen (NASDAQ:AMGN) has been hit hard over the last year on drug pricing news. Key blockbusters like Enbrel and Neulasta are two of the most prescribed drugs in their categories and mint cash for AMGN. Those blockbusters, as well as others, such as Repatha, blood-cancer drug Kyprolis and bone-density drug Prolia, are the reasons why Amgen has become a dividend and buyback stalwart. Their high prices are also the reason why AMGN is in the crosshairs of lawmakers.Despite that and the drop in AMGN stock, investors may want to consider the firm.For one thing, Amgen continues to dive head first into more advanced cancer and gene therapy drugs. These specialized drugs are naturally higher cost. There's very little that regulation can do for them. With data from Amgen's new cancer therapies crushing the trial, there's a good chance that the firm will have another blockbuster in its arsenal. And we can't forget about its massive pipeline either.In the end, AMGN will be pretty immune from the effects of regulation and will continue to rack up massive cash flows from specialized drugs. That should help pad its now 3.32% dividend for years to come. Stryker Corporation (SYK)Source: Shutterstock Artificial knees, hospital beds and even specialized bone cement … medical device company Stryker (NYSE:SYK) has it all. And that could make it a top healthcare stock contender to snag-up in the recent sector wreckage. SYK has its hands in many pots and that will allow it to handle anything the government throws at it.This is evident by its continued surge in sales and revenues. Last quarter, SYK managed to see a big 8.5% jump in net sales. The key was that divisions featuring more high-tech devices and products, such as orthopedics and neurotechnology, saw big double-digit sales gains. The medical device firm has continued to boost these divisions with smart M&A as well as new innovative internal product launches. That's a good thing as these higher-tech areas are seen as being more insulated to regulation. For Stryker and its shareholders, this could be gold for the long haul.Speaking of that gold, SYK has been sharing the wealth with investors as well. The firm's latest dividend represents a big 11% increase. At the same time, Stryker has been a buyback champ as well -- reducing its share count by about $1 billion last year. * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right With a forward P/E of 22, Stryker isn't super cheap, but considering its growth estimates and potential to keep the good times going in the face of regulation, that could seem like a bargain. Bristol-Myers Squibb (BMY)Source: A 4 via Flickr It's not surprising that old-school pharma has been hit hard in recent weeks. But there's nothing particularly old school about Bristol-Myers Squibb (NYSE:BMY). That's because BMY has quickly become the anti-cancer and advanced drug machine.BMY already had top blockbuster cancer-fighter Opdivo, which pulls in more than $2 billion in quarterly revenues for the firm. But thanks to its recent $74 billion out of Celgene (NASDAQ:CELG), Bristol-Meyers will have one of the richest oncology portfolios around. This includes blockbusters Yervoy, Revlimid and Pomalyst which will all now be under its umbrella. This doesn't even include CELG's rich pipeline nor BMY's own advanced cancer-fighting drugs under development.As we said before, specialized cancer drugs are big revenues drivers and given just how advanced they are, the government may have little ability to regulate them. This should help drive revenues and cash flows at Bristol-Meyer's for years to come. And yes, patent expiration for Revlimid is coming down the pike. But under BMY's vast portfolio of drugs, that expiration means less than when it was CELG's chief revenue driver.Yet, BMY trades at a real discount to other big healthcare stocks. For investors, the top and future cancer fighter offers a great long-term play at cheap prices.As of this writing, Aaron Levitt was long AMGN and ABMD. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post 5 Healthcare Stocks to Pick Up From the Wreckage appeared first on InvestorPlace.
Pull up a chart on top healthcare stock CVS Health (NYSE:CVS) and the results aren't pretty. CVS stock has spent the better part of the last five years heading lower. And in fact, CVS has managed to underperform the S&P 500 and the broader healthcare sector by a wide margin. This year alone, CVS stock is down by almost 15%.Source: Mike Mozart via FlickrWhile the part of that has to do with continued fear of pending regulation and government intervention in the healthcare market, the main part continues to be the firm's shift from being simply a pharmacy into something more.CVS has moved into being a total healthcare and wellness provider. Its buyout of insurer Aetna furthers that move. And with management touting some new initiatives at its investor day, CVS stock is fully taking the plunge into being a one-stop shop for Americans.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe question is, will the moves work? CVS's transition continue to be a risky one for investors. However, its new plans may actually pan out. CVS Stock Makes It All About HealthThe healthcare sector is always changing, and for CVS that meant moving beyond simply being a drug and retail outlet. To that end, CVS has bet big bucks on transitioning itself from a strictly healthcare-related retail stock into more of a total package. It bought Caremark, then nursing home/long-term care facility drug distributor Omnicare and now health insurer Aetna. These moves made the firm one of the leading benefits managers in the nation. * 6 Big Dividend Stocks to Buy as Yields Plunge Since then, CVS has started to model its stores into more one-stop shops for all healthcare needs. They stopped selling cigarettes and added about 1,100 MinuteClinics to its stores. These walk-in clinics were designed to allow customers to get flu shots, basic diagnoses and pick-up a prescription for maintenance medications or simple illnesses.And now the firm has continued to transition even further. After positive testing, CVS is prepared to unveil its new CVS HealthHub concept at roughly 1,500 stores. These HealthHub locations will feature expanded health clinic operations, including labs for blood work and health screenings. This could include genetic and other disease testing. Additionally, several locations will be staffed by healthcare specialists such as dietitians and even eye specialists. Finally, CVS plans on adding so-called wellness rooms to these locations. Here, customers can take a yoga class or attend a seminar on say, diabetes care. CVS May Finally Get It RightWhile it may easy to laugh at the idea of taking a yoga class at your local CVS, the new HealthHub concept and roll-out may actually pay some serious benefits for the retail chain.First of all, it gets CVS ahead of online rivals. Amazon (NASDAQ:AMZN) has long hinted that it plans on getting into the pharmacy game and has continued to beef up its presence for generic, over-the-counter medications.Secondly, telemedicine rivals like Teledoc (NSDAQ:TDOC) have surged in popularity with consumers for basic diagnoses. However, CVS has a potential win here with its new roll-out. Health services are one of the few areas untouchable by online means. Additionally, one of the drawbacks to TDOC is that you still need to make a trip to the pharmacy to pick up a prescription. With its MinuteClinics and HealthHubs, consumers are already in a location that can deliver that medication. It's one stop, instead of two.And there is the opportunity to upsell items as well. Consumers can grab other items that come with juicer margins -- beverages, toilet paper, gallons of milk, etc. -- while at the stores. After a vigorous yoga session, it becomes very easy for CVS to prominently display healthier snacks and drinks right outside its wellness rooms.Then there is the health insurance angle to consider. Health insurance companies make money by having their users NOT get sick. For Aetna to boost its profitability, it pays for CVS to keep its members healthy. By offering these wellness programs, checkups and maintenance products, it can keep its members outside hospitals and potentially keep them from needing more intensive care in the first place. Still A Risky BetThe transition for CVS into being a full wellness stock has a ton of potential. It'll allow the firm to fight online rivals, give people a reason to enter its stores and potentially make its insurance operations that much better. The question is, can it work?I think it can, but it won't be a walk in the park. CVS seriously needs to boost its customer service aspects to make the HealthHub concept a reality. In general, CVS is sort of a mixed bag when it comes to customer services. It seems that stores are either very well operated or they are terrible locations with no employees working. It'll take plenty of dollars to make this happen. It hinted at the "billions in new tech" that it'll need to invest to make the concept a reality. Without the CAPEX spend, this could turn into a joke. "Remember when CVS used to offer yoga classes?"That needed spending could be an issue considering that it now has to pay for the $70 billion Aetna acquisition. Already, Omnicare has proved to be a tough pill to swallow. With regulatory pressures mounting, CVS may have a tough time getting the concept up and running effectively.But it's a gamble that investors may want to look at. CVS stock can currently be had for a dirt-cheap forward P/E of about 8 and it does pay a 3.6% dividend yield. At least it's doing something to boost its long-term potential in the face of new rivals.At the time of writing, Aaron Levitt was long AMZN stock. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post Can the CVS Shift to a Total Healthcare Company Really Work? appeared first on InvestorPlace.
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc Health (TDOC), the global leader in virtual care, announces that it has established the healthcare industry’s first Patient Safety Organization (PSO) dedicated to virtual care. Listed and certified by the Agency for Healthcare Research and Quality (AHRQ) effective May 8, 2019, this newly formed component entity of Teladoc Health is formally recognized by the Department of Health and Human Services (HHS) as The Institute for Patient Safety and Quality of Virtual Care. The organization will conduct quality and safety initiatives with and on behalf of key healthcare stakeholders, including other PSOs, to improve the delivery of virtual care across the country.
The market desperately wants to put an end to the lingering trade war, but President Trump seemingly has other ideas. Cramer said our economy is certainly strong enough to handle this blow, but not if combined with what's likely coming next.
Sometimes the U.S. stock market sends a clear, unambiguous message. The message the stock market sent during Federal Reserve Chairman Jerome Powell’s press conference Wednesday says that the market is vulnerable. • The chart shows that the stock market rose immediately after the Fed decision was announced.